IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v470y2011i7333d10.1038_nature09677.html
   My bibliography  Save this article

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

Author

Listed:
  • Zhihu Ding

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

  • Chang-Jiun Wu

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

  • Gerald C. Chu

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Brigham and Women’s Hospital)

  • Yonghong Xiao

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Dennis Ho

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

  • Jingfang Zhang

    (McArdle Lab for Cancer Research, University of Wisconsin)

  • Samuel R. Perry

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Emma S. Labrot

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Xiaoqiu Wu

    (Dana-Farber Cancer Institute
    Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute)

  • Rosina Lis

    (Dana-Farber Cancer Institute
    Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute)

  • Yujin Hoshida

    (Pediatric Oncology, Dana-Farber Cancer Institute
    The Eli and Edythe L. Broad Institute, Massachusetts Institute of Technology and Harvard University)

  • David Hiller

    (Stanford University)

  • Baoli Hu

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Shan Jiang

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Hongwu Zheng

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

  • Alexander H. Stegh

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

  • Kenneth L. Scott

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

  • Sabina Signoretti

    (Renal Cancer Program, Dana-Farber/Harvard Cancer Center)

  • Nabeel Bardeesy

    (Massachusetts General Hospital Cancer Center)

  • Y. Alan Wang

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • David E. Hill

    (Harvard Medical School
    Dana-Farber Cancer Institute)

  • Todd R. Golub

    (Pediatric Oncology, Dana-Farber Cancer Institute
    The Eli and Edythe L. Broad Institute, Massachusetts Institute of Technology and Harvard University)

  • Meir J. Stampfer

    (Harvard School of Public Health
    Harvard School of Public Health
    Channing Laboratory, Brigham and Women’s Hospital)

  • Wing H. Wong

    (Stanford University)

  • Massimo Loda

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital
    Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute)

  • Lorelei Mucci

    (Harvard School of Public Health
    Channing Laboratory, Brigham and Women’s Hospital)

  • Lynda Chin

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

  • Ronald A. DePinho

    (Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Harvard Medical School
    Harvard Medical School)

Abstract

Four-gene marker in prostate cancer Using a Smad4/Pten null transgenic mouse model of prostate cancer, Ding et al. show that the transforming growth factor-β (TGFβ) signalling pathway limits tumour progression and metastasis. By utilizing markers of this pathway and other biologically relevant factors, they develop a four-gene signature that is associated with poorer clinical outcome and metastatic progression in several prostate cancer cohorts, especially in combination with other clinical parameters. This signature may prove useful as a basis for an improved prognostic test for those cases of prostate cancer in which deciding on the right treatment regime while avoiding over-treatment is an important clinical challenge.

Suggested Citation

  • Zhihu Ding & Chang-Jiun Wu & Gerald C. Chu & Yonghong Xiao & Dennis Ho & Jingfang Zhang & Samuel R. Perry & Emma S. Labrot & Xiaoqiu Wu & Rosina Lis & Yujin Hoshida & David Hiller & Baoli Hu & Shan Ji, 2011. "SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression," Nature, Nature, vol. 470(7333), pages 269-273, February.
    • Handle: RePEc:nat:nature:v:470:y:2011:i:7333:d:10.1038_nature09677
    DOI: 10.1038/nature09677
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature09677
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature09677?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Michael Fraser & Julie Livingstone & Jeffrey L. Wrana & Antonio Finelli & Housheng Hansen He & Theodorus van der Kwast & Alexandre R. Zlotta & Robert G. Bristow & Paul C. Boutros, 2021. "Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    2. Ni Li & Qiuli Liu & Ying Han & Siyu Pei & Bisheng Cheng & Junyu Xu & Xiang Miao & Qiang Pan & Hanling Wang & Jiacheng Guo & Xuege Wang & Guoying Zhang & Yannan Lian & Wei Zhang & Yi Zang & Minjia Tan , 2022. "ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression," Nature Communications, Nature, vol. 13(1), pages 1-20, December.
    3. Huiqiang Cai & Bin Zhang & Johanne Ahrenfeldt & Justin V. Joseph & Maria Riedel & Zongliang Gao & Sofie K. Thomsen & Ditte S. Christensen & Rasmus O. Bak & Henrik Hager & Mikkel H. Vendelbo & Xin Gao , 2024. "CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:470:y:2011:i:7333:d:10.1038_nature09677. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.